Patient characteristics according to number of matching alleles
| Variable . | 8 of 8 alleles matched, no. (%) [no. eval] . | 7 of 8 alleles matched, no. (%) [no. eval] . | 6 of 8 alleles matched, no. (%) [no. eval] . | 5 or fewer of 8 alleles matched, no. (%) [no. eval] . |
|---|---|---|---|---|
| No. patients | 1840 | 985 | 633 | 399 |
| No. centers | 105 | 100 | 94 | 75 |
| Median age, y (range) | 35 (<1-65) [1839] | 31 (<1-65) [985] | 28 (<1-59) [633] | 28 (<1-55) [399] |
| Age at transplantation, y | [1839] | [985] | [633] | [399] |
| Younger than 11 | 167 (9) | 118 (12) | 79 (12) | 67 (17) |
| 11 to 20 | 194 (11) | 153 (16) | 135 (21) | 66 (17) |
| 21 to 30 | 328 (18) | 175 (18) | 117 (18) | 78 (20) |
| 31 to 40 | 452 (25) | 222 (23) | 142 (22) | 103 (26) |
| 41 to 50 | 479 (26) | 229 (23) | 127 (20) | 67 (17) |
| Older than 50 | 219 (12) | 88 (9) | 33 (5) | 18 (5) |
| Race | [1840] | [985] | [632] | [399] |
| White | 1715 (93) | 858 (87) | 504 (80) | 264 (66) |
| Black | 44 (2) | 50 (5) | 38 (6) | 57 (14) |
| Hispanic | 54 (3) | 53 (5) | 63 (10) | 51 (13) |
| Other | 27 (2) | 24 (3) | 27 (4) | 27 (7) |
| Recipient sex, male | 1041 (57) [1840] | 537 (55) [985] | 361 (57) [633] | 244 (61) [399] |
| Karnofsky prior to TX, 90 or higher | 1328 (74) [1784] | 713 (74) [962] | 453 (73) [622] | 298 (76) [393] |
| HLA-A, -B, -C, -DRB1 matching | [1840] | [985] | [633] | [399] |
| Allele matched | 1840 (100) | 0 | 0 | 0 |
| Single allele mismatch (MM) | 0 | 412 (42) | 0 | 0 |
| Two allele MM | 0 | 0 | 105 (16) | 0 |
| Three or more allele MM | 0 | 0 | 0 | 10 (3) |
| Single antigen MM | 0 | 573 (58) | 0 | 0 |
| Two antigen MM | 0 | 0 | 239 (38) | 0 |
| Three or more antigen MM | 0 | 0 | 0 | 36 (9) |
| One or more allele MM and 1 or more antigen MM | 0 | 0 | 289 (46) | 353 (88) |
| Disease at transplantation | [1840] | [985] | [633] | [399] |
| AML | 496 (27) | 294 (30) | 179 (28) | 86 (21) |
| ALL | 410 (22) | 253 (26) | 171 (27) | 118 (30) |
| CML | 759 (41) | 366 (37) | 242 (38) | 175 (44) |
| MDS | 175 (10) | 72 (7) | 41 (7) | 20 (5) |
| Disease status at transplantation | [1840] | [985] | [633] | [399] |
| Early | 835 (45) | 378 (38) | 241 (38) | 149 (37) |
| Intermediate | 674 (37) | 410 (42) | 268 (42) | 180 (45) |
| Advanced | 327 (18) | 195 (20) | 123 (19) | 69 (17) |
| Unknown | 4 (<1) | 2 (<1) | 1 (<1) | 1 (<1) |
| Conditioning regimen, TBI based | 1492 (81) [1840] | 807 (82) [985] | 553 (87) [633] | 357 (89) [399] |
| GVHD prophylaxis, T-cell depleted | 307 (17) [1840] | 241 (24) [985] | 167 (26) [633] | 115 (29) [399] |
| Graft type | [1840] | [985] | [633] | [399] |
| Bone marrow | 1698 (92) | 916 (93) | 604 (95) | 397 (99) |
| PBSC | 142 (8) | 69 (7) | 29 (5) | 2 (1) |
| Donor/recipient sex match | [1840] | [985] | [633] | [399] |
| Male/male | 717 (39) | 331 (34) | 198 (31) | 135 (34) |
| Male/female | 446 (24) | 237 (24) | 141 (22) | 74 (19) |
| Female/male | 324 (18) | 206 (21) | 163 (26) | 109 (27) |
| Female/female | 353 (19) | 211 (21) | 131 (21) | 81 (20) |
| Donor/recipient CMV match | [1840] | [985] | [633] | [399] |
| Negative/negative | 667 (36) | 341 (35) | 201 (32) | 104 (26) |
| Negative/positive | 516 (28) | 266 (27) | 187 (30) | 118 (30) |
| Positive/negative | 298 (16) | 160 (16) | 97 (15) | 77 (19) |
| Positive/positive | 303 (17) | 192 (19) | 128 (20) | 90 (23) |
| Unknown | 56 (3) | 26 (3) | 20 (3) | 10 (2) |
| Donor age, median (range), y | 36 (18-60) [1840] | 36 (19-59) [985] | 36 (18-59) [633] | 36 (19-60) [399] |
| Donor age, y | [1840] | [985] | [633] | [399] |
| 18 to 19 | 15 (1) | 6 (1) | 5 (1) | 3 (1) |
| 20 to 29 | 463 (25) | 237 (24) | 161 (25) | 102 (25) |
| 30 to 39 | 726 (39) | 376 (38) | 238 (38) | 146 (37) |
| 40 to 49 | 511 (28) | 284 (29) | 186 (29) | 119 (30) |
| 50 and older | 125 (7) | 82 (8) | 43 (7) | 29 (7) |
| Year of transplantation | [1840] | [985] | [633] | [399] |
| 1988 to 1989 | 44 (2) | 19 (2) | 17 (3) | 18 (5) |
| 1990 to 1994 | 432 (24) | 224 (23) | 182 (29) | 140 (35) |
| 1995 to 1999 | 787 (43) | 441 (45) | 292 (46) | 176 (44) |
| 2000 to 2003 | 577 (31) | 301 (30) | 142 (22) | 65 (16) |
| Median follow-up of survivors, mo | 73 (3-194) [671] | 63 (6-191) [297] | 84 (11-192) [134] | 96 (4-183) [75] |
| Variable . | 8 of 8 alleles matched, no. (%) [no. eval] . | 7 of 8 alleles matched, no. (%) [no. eval] . | 6 of 8 alleles matched, no. (%) [no. eval] . | 5 or fewer of 8 alleles matched, no. (%) [no. eval] . |
|---|---|---|---|---|
| No. patients | 1840 | 985 | 633 | 399 |
| No. centers | 105 | 100 | 94 | 75 |
| Median age, y (range) | 35 (<1-65) [1839] | 31 (<1-65) [985] | 28 (<1-59) [633] | 28 (<1-55) [399] |
| Age at transplantation, y | [1839] | [985] | [633] | [399] |
| Younger than 11 | 167 (9) | 118 (12) | 79 (12) | 67 (17) |
| 11 to 20 | 194 (11) | 153 (16) | 135 (21) | 66 (17) |
| 21 to 30 | 328 (18) | 175 (18) | 117 (18) | 78 (20) |
| 31 to 40 | 452 (25) | 222 (23) | 142 (22) | 103 (26) |
| 41 to 50 | 479 (26) | 229 (23) | 127 (20) | 67 (17) |
| Older than 50 | 219 (12) | 88 (9) | 33 (5) | 18 (5) |
| Race | [1840] | [985] | [632] | [399] |
| White | 1715 (93) | 858 (87) | 504 (80) | 264 (66) |
| Black | 44 (2) | 50 (5) | 38 (6) | 57 (14) |
| Hispanic | 54 (3) | 53 (5) | 63 (10) | 51 (13) |
| Other | 27 (2) | 24 (3) | 27 (4) | 27 (7) |
| Recipient sex, male | 1041 (57) [1840] | 537 (55) [985] | 361 (57) [633] | 244 (61) [399] |
| Karnofsky prior to TX, 90 or higher | 1328 (74) [1784] | 713 (74) [962] | 453 (73) [622] | 298 (76) [393] |
| HLA-A, -B, -C, -DRB1 matching | [1840] | [985] | [633] | [399] |
| Allele matched | 1840 (100) | 0 | 0 | 0 |
| Single allele mismatch (MM) | 0 | 412 (42) | 0 | 0 |
| Two allele MM | 0 | 0 | 105 (16) | 0 |
| Three or more allele MM | 0 | 0 | 0 | 10 (3) |
| Single antigen MM | 0 | 573 (58) | 0 | 0 |
| Two antigen MM | 0 | 0 | 239 (38) | 0 |
| Three or more antigen MM | 0 | 0 | 0 | 36 (9) |
| One or more allele MM and 1 or more antigen MM | 0 | 0 | 289 (46) | 353 (88) |
| Disease at transplantation | [1840] | [985] | [633] | [399] |
| AML | 496 (27) | 294 (30) | 179 (28) | 86 (21) |
| ALL | 410 (22) | 253 (26) | 171 (27) | 118 (30) |
| CML | 759 (41) | 366 (37) | 242 (38) | 175 (44) |
| MDS | 175 (10) | 72 (7) | 41 (7) | 20 (5) |
| Disease status at transplantation | [1840] | [985] | [633] | [399] |
| Early | 835 (45) | 378 (38) | 241 (38) | 149 (37) |
| Intermediate | 674 (37) | 410 (42) | 268 (42) | 180 (45) |
| Advanced | 327 (18) | 195 (20) | 123 (19) | 69 (17) |
| Unknown | 4 (<1) | 2 (<1) | 1 (<1) | 1 (<1) |
| Conditioning regimen, TBI based | 1492 (81) [1840] | 807 (82) [985] | 553 (87) [633] | 357 (89) [399] |
| GVHD prophylaxis, T-cell depleted | 307 (17) [1840] | 241 (24) [985] | 167 (26) [633] | 115 (29) [399] |
| Graft type | [1840] | [985] | [633] | [399] |
| Bone marrow | 1698 (92) | 916 (93) | 604 (95) | 397 (99) |
| PBSC | 142 (8) | 69 (7) | 29 (5) | 2 (1) |
| Donor/recipient sex match | [1840] | [985] | [633] | [399] |
| Male/male | 717 (39) | 331 (34) | 198 (31) | 135 (34) |
| Male/female | 446 (24) | 237 (24) | 141 (22) | 74 (19) |
| Female/male | 324 (18) | 206 (21) | 163 (26) | 109 (27) |
| Female/female | 353 (19) | 211 (21) | 131 (21) | 81 (20) |
| Donor/recipient CMV match | [1840] | [985] | [633] | [399] |
| Negative/negative | 667 (36) | 341 (35) | 201 (32) | 104 (26) |
| Negative/positive | 516 (28) | 266 (27) | 187 (30) | 118 (30) |
| Positive/negative | 298 (16) | 160 (16) | 97 (15) | 77 (19) |
| Positive/positive | 303 (17) | 192 (19) | 128 (20) | 90 (23) |
| Unknown | 56 (3) | 26 (3) | 20 (3) | 10 (2) |
| Donor age, median (range), y | 36 (18-60) [1840] | 36 (19-59) [985] | 36 (18-59) [633] | 36 (19-60) [399] |
| Donor age, y | [1840] | [985] | [633] | [399] |
| 18 to 19 | 15 (1) | 6 (1) | 5 (1) | 3 (1) |
| 20 to 29 | 463 (25) | 237 (24) | 161 (25) | 102 (25) |
| 30 to 39 | 726 (39) | 376 (38) | 238 (38) | 146 (37) |
| 40 to 49 | 511 (28) | 284 (29) | 186 (29) | 119 (30) |
| 50 and older | 125 (7) | 82 (8) | 43 (7) | 29 (7) |
| Year of transplantation | [1840] | [985] | [633] | [399] |
| 1988 to 1989 | 44 (2) | 19 (2) | 17 (3) | 18 (5) |
| 1990 to 1994 | 432 (24) | 224 (23) | 182 (29) | 140 (35) |
| 1995 to 1999 | 787 (43) | 441 (45) | 292 (46) | 176 (44) |
| 2000 to 2003 | 577 (31) | 301 (30) | 142 (22) | 65 (16) |
| Median follow-up of survivors, mo | 73 (3-194) [671] | 63 (6-191) [297] | 84 (11-192) [134] | 96 (4-183) [75] |
No. eval indicates the number evaluable for each characteristic; TX, transplantation; and PBSC, peripheral blood stem cell.